KRAS and neoplasm of thorax: Our NGS analysis of 27 SMARCA4‐deficient thoracic tumors identified frequent mutations in TP53, CDKN2A, KRAS, STK11, NF1, and PTEN, with rare actionable oncogenic driver mutations.6, 17